Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174078113> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W3174078113 endingPage "OR" @default.
- W3174078113 startingPage "89" @default.
- W3174078113 abstract "While intravenous anti-VEGF agents are known to contribute to arterial thromboembolic events, the cardiovascular (CV) safety of intravitreal anti-VEGF inhibitors remain unclear. Using Medicare and 2 U.S. commercial claims datasets (1/2009-12/2017), we identified 1:1 propensity score matched patients aged ≥18 years with DR initiating treatment with (1) intravitreal anti-VEGF injections or (2) laser procedure or intravitreal steroid injections (30,681 matched pairs). We assessed a composite CV outcome [myocardial infarction (MI) or stroke], its individual components, and mortality, using an intention-to-treat (ITT) scheme censoring at 180 days and 365 days of follow-up. We estimated pooled HRs and 95% CIs adjusting for 85 baseline covariates. Compared to laser or steroid treatment, intravitreal anti-VEGF injections were associated with a similar risk of the composite CV outcome [HR:0.91 (95% CI:078, 1.06)], MI [0.91 (0.74, 1.11)], stroke [0.92 (0.74, 1.15)], or risk of mortality [1.14 (0.87, 1.51)] at 6 months of follow up. Results were consistent in an ITT analysis censoring at 365 days (Table). Intravitreal anti-VEGF injections, compared to laser or steroid treatment, had similar risk of CV events and mortality in patients with DR. Disclosure M. Roh: None. H. Tesfaye: None. L. P. Aiello: Consultant; Self; KalVista Pharmaceuticals, Novo Nordisk, Regeneron Pharmaceuticals Inc., Stock/Shareholder; Self; KalVista Pharmaceuticals. S. C. Kim: Research Support; Self; AbbVie Inc., Bristol-Myers Squibb Company, Pfizer Inc., Roche Pharma. E. Patorno: Research Support; Self; Boehringer Ingelheim International GmbH, National Institutes of Health." @default.
- W3174078113 created "2021-07-05" @default.
- W3174078113 creator A5008078906 @default.
- W3174078113 creator A5042011351 @default.
- W3174078113 creator A5044474781 @default.
- W3174078113 creator A5074777366 @default.
- W3174078113 creator A5090636908 @default.
- W3174078113 date "2021-06-01" @default.
- W3174078113 modified "2023-09-23" @default.
- W3174078113 title "89-OR: Cardiovascular and Mortality Risk with Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Inhibitors in Patients with Diabetic Retinopathy (DR)" @default.
- W3174078113 doi "https://doi.org/10.2337/db21-89-or" @default.
- W3174078113 hasPublicationYear "2021" @default.
- W3174078113 type Work @default.
- W3174078113 sameAs 3174078113 @default.
- W3174078113 citedByCount "0" @default.
- W3174078113 crossrefType "journal-article" @default.
- W3174078113 hasAuthorship W3174078113A5008078906 @default.
- W3174078113 hasAuthorship W3174078113A5042011351 @default.
- W3174078113 hasAuthorship W3174078113A5044474781 @default.
- W3174078113 hasAuthorship W3174078113A5074777366 @default.
- W3174078113 hasAuthorship W3174078113A5090636908 @default.
- W3174078113 hasConcept C118487528 @default.
- W3174078113 hasConcept C126322002 @default.
- W3174078113 hasConcept C134018914 @default.
- W3174078113 hasConcept C167734588 @default.
- W3174078113 hasConcept C2777025900 @default.
- W3174078113 hasConcept C2778313320 @default.
- W3174078113 hasConcept C2779829184 @default.
- W3174078113 hasConcept C50440223 @default.
- W3174078113 hasConcept C555293320 @default.
- W3174078113 hasConcept C71924100 @default.
- W3174078113 hasConceptScore W3174078113C118487528 @default.
- W3174078113 hasConceptScore W3174078113C126322002 @default.
- W3174078113 hasConceptScore W3174078113C134018914 @default.
- W3174078113 hasConceptScore W3174078113C167734588 @default.
- W3174078113 hasConceptScore W3174078113C2777025900 @default.
- W3174078113 hasConceptScore W3174078113C2778313320 @default.
- W3174078113 hasConceptScore W3174078113C2779829184 @default.
- W3174078113 hasConceptScore W3174078113C50440223 @default.
- W3174078113 hasConceptScore W3174078113C555293320 @default.
- W3174078113 hasConceptScore W3174078113C71924100 @default.
- W3174078113 hasIssue "Supplement 1" @default.
- W3174078113 hasLocation W31740781131 @default.
- W3174078113 hasOpenAccess W3174078113 @default.
- W3174078113 hasPrimaryLocation W31740781131 @default.
- W3174078113 hasRelatedWork W2007632404 @default.
- W3174078113 hasRelatedWork W2093343485 @default.
- W3174078113 hasRelatedWork W2171597431 @default.
- W3174078113 hasRelatedWork W2354576886 @default.
- W3174078113 hasRelatedWork W2364888521 @default.
- W3174078113 hasRelatedWork W2370848294 @default.
- W3174078113 hasRelatedWork W2371029630 @default.
- W3174078113 hasRelatedWork W2371794002 @default.
- W3174078113 hasRelatedWork W2377184508 @default.
- W3174078113 hasRelatedWork W4200596730 @default.
- W3174078113 hasVolume "70" @default.
- W3174078113 isParatext "false" @default.
- W3174078113 isRetracted "false" @default.
- W3174078113 magId "3174078113" @default.
- W3174078113 workType "article" @default.